Multiple Sclerosis Research Repository

“Disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis” Lucchetta RC et al

-The most effective therapies for the outcome of annualised relapse rate were alemtuzumab (96% probability), natalizumab (96%) and ocrelizumab (85%), compared with all other therapies (hazard ratio versus placebo, 0.31, 0.31 and 0.37, respectively; p < 0.05 for all comparisons) (high-quality evidence)

-*Says NOTHING in abstract about disability progression!*